Drug General Information |
Drug ID |
D06WHY
|
Former ID |
DNC009585
|
Drug Name |
AZD-5438
|
Drug Type |
Small molecular drug
|
Indication |
Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48]
|
Phase 1 |
[1],
[2]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C18H21N5O2S
|
InChI |
InChI=1S/C18H21N5O2S/c1-12(2)23-13(3)20-11-17(23)16-9-10-19-18(22-16)21-14-5-7-15(8-6-14)26(4,24)25/h5-12H,1-4H3,(H,19,21,22)
|
InChIKey |
WJRRGYBTGDJBFX-UHFFFAOYSA-N
|
PubChem Compound ID |
|
PubChem Substance ID |
26733716, 40162541, 46577688, 103589138, 104101719, 109692765, 123051130, 123124466, 124360785, 125164698, 125649588, 126646527, 126671311, 126731229, 134346790, 135262197, 135723837, 136340356, 136368076, 136920425, 143498613, 144115656, 152237513, 152258057, 152344093, 160646895, 162011563, 162038016, 162140080, 162202622, 165238063, 170495574, 172131335, 174007078, 174529963, 180371712, 184824934, 223399391, 223675677, 223704699, 223948759, 230957049, 241123037, 242060358, 247152154, 251971188, 252157678, 252160611, 252166682, 252214925
|
Target and Pathway |
Target(s) |
Cell division protein kinase 2 |
Target Info |
Modulator |
[1]
|
KEGG Pathway
|
FoxO signaling pathway
|
Cell cycle
|
Oocyte meiosis
|
p53 signaling pathway
|
PI3K-Akt signaling pathway
|
Progesterone-mediated oocyte maturation
|
Hepatitis B
|
Measles
|
Herpes simplex infection
|
Epstein-Barr virus infection
|
Pathways in cancer
|
Viral carcinogenesis
|
Prostate cancer
|
Small cell lung cancer
|
NetPath Pathway
|
TCR Signaling Pathway
|
PANTHER Pathway
|
p53 pathway
|
p53 pathway feedback loops 2
|
Pathway Interaction Database
|
Regulation of nuclear SMAD2/3 signaling
|
Signaling events mediated by PRL
|
p73 transcription factor network
|
E2F transcription factor network
|
ATR signaling pathway
|
mTOR signaling pathway
|
IL2-mediated signaling events
|
FoxO family signaling
|
FOXM1 transcription factor network
|
BARD1 signaling events
|
p53 pathway
|
Regulation of retinoblastoma protein
|
Reactome
|
G0 and Early G1
|
Activation of ATR in response to replication stress
|
Regulation of APC/C activators between G1/S and early anaphase
|
SCF(Skp2)-mediated degradation of p27/p21
|
Senescence-Associated Secretory Phenotype (SASP)
|
DNA Damage/Telomere Stress Induced Senescence
|
Processing of DNA double-strand break ends
|
G2 Phase
|
Orc1 removal from chromatin
|
Cyclin E associated events during G1/S transition
|
Cyclin A/B1 associated events during G2/M transition
|
p53-Dependent G1 DNA Damage Response
|
Cyclin A:Cdk2-associated events at S phase entry
|
Meiotic recombination
|
Factors involved in megakaryocyte development and platelet production
|
WikiPathways
|
DNA Damage Response
|
ID signaling pathway
|
DNA Replication
|
G1 to S cell cycle control
|
M/G1 Transition
|
S Phase
|
Meiotic Recombination
|
Aryl Hydrocarbon Receptor
|
ATM Signaling Pathway
|
Retinoblastoma (RB) in Cancer
|
Spinal Cord Injury
|
Integrated Pancreatic Cancer Pathway
|
Oncostatin M Signaling Pathway
|
Prostate Cancer
|
Signaling Pathways in Glioblastoma
|
TSH signaling pathway
|
Integrated Breast Cancer Pathway
|
Integrated Cancer pathway
|
Synthesis of DNA
|
Regulation of DNA replication
|
Mitotic G2-G2/M phases
|
Mitotic G1-G1/S phases
|
Factors involved in megakaryocyte development and platelet production
|
Cell Cycle
|
APC/C-mediated degradation of cell cycle proteins
|
Cell Cycle Checkpoints
|
miRNA Regulation of DNA Damage Response
|
References |
REF 1 | AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts. Mol Cancer Ther. 2009 Jul;8(7):1856-66. |
---|
REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8473). |